Capivasertib China PK study

Trial Identifier: D3614C00002
Sponsor: AstraZeneca
NCTID:: NCT04742036
Start Date: February 2021
Primary Completion Date: July 2022
Study Completion Date: July 2022
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Chinese (China) Translation

Trial Locations

Country Location
CN Shanghai, CN, 200032